RIGL
RigelBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The best post-earnings bull read is that Q1 still showed 26% year-over-year net product sales growth, another profitable quarter, $146.7 million of cash and short-term investments at March 31, 2026, and reaffirmed 2026 revenue guidance despite the Lilly reset, which supports a monitoring-style constructive view rather than a broken thesis [#8-K-2026-05-05] [#10-Q-2026-05-05].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Commercial products still face the usual biotech risks around demand variability, competition, pricing, reimbursement, and regulatory decisions noted in the company’s forward-looking disclosures [#8-K-2026-05-05].
Momentum
91
Value
71
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $40.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $54.20
Why
Momentum91 · Δ7d -3.7
Value71 · Δ7d +0.2
Sentiment20 · Δ7d +1.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
91
26% active weight
Current posture
7d trendSoftening
Δ7d
-3.7
Δ21d
+14.6
Value
71
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.1
Sentiment
20
34% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
-4.1
Why this grade
Composite grade B. Momentum 91.4 / Value 71.1 / Sentiment 19.9
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$727.32M
Beta
1.11
Shares Out
18.5M
P/E (TTM)
6.7
P/S (TTM)
2.65
P/FCF (TTM)
10.97
Rev YoY
+10.3%
EPS YoY
-30.2%
Gross Margin
+93.4%
Op Margin
+42.2%
Net Debt
-$101.65M
Current Ratio
2.62
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology